Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mean effective dose of sufentanil for suppressing laryngeal mask insertion responses in elderly patients
ChiCTR2100051827Phase 4Not yet recruiting
- Sponsor
- Anqing Municipal Hospital
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sufentanil (6 arms), sponsored by Anqing Municipal Hospital. Primary endpoints: Blood pressure, Heart rate and 2 more. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
sufentanil
Beyond the preview
Go deeper on ChiCTR2100051827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051827.